Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Journal of the American Academy of Dermatology|November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Advances in Therapy|July 22, 2021
Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance ClaimsMaryanne Senna, Justin Ko, Antonella Tosti, et al.
Dermatology and Therapy|April 16, 2026
How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based ApproachBrett King, Maryanne Senna, Manabu Ohyama, et al.
The Journal of Allergy and Clinical Immunology|December 15, 2020
Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinibAlice Wang, Nur-Taz Rahman, Meaghan K McGeary, et al.
American Journal of Clinical Dermatology|April 7, 2021
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical TrialsBrett King, Catherine Maari, Edward Lain, et al.
Dermatology and Therapy|June 30, 2022
Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI)Helen Kitchen, Kathleen W Wyrwich, Chloe Carmichael, et al.
Journal of the American Academy of Dermatology|March 18, 2020
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case seriesRana Abdat, Reid A Waldman, Valeria de Bedout, et al.
The Journal of Investigative Dermatology|May 23, 2025
Cutaneous Lupus Features Specialized Stromal Niches and Altered Retroelement ExpressionJeff R Gehlhausen, Yong Kong, Emily Baker, et al.
Journal of the American Academy of Dermatology|October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2Brett King, Manabu Ohyama, Maryanne Senna, et al.
American Journal of Clinical Dermatology|March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Pageof 8